Figitumumab Terminated Naked monospecific

Antibody Information

Entry ID	2004
INN	Figitumumab
Status	Terminated
Drug code(s)	CP-751,871
Brand name	None
mAb sequence source	mAb human
General Molecular Category	Naked monospecific
Format, general category	Full length Ab
Format details	None
Isotype (Fc)	IgG2
Light chain isotype	kappa
Linker	None
Ave. DAR	None
Conjugated/fused moiety	None
Discovery method/technology	Transgenic mouse-derived (Xenomouse)

Therapeutic information

Target(s)	IGF-1R
Indications of clinical studies	Non-small cell lung cancer, multiple myeloma, breast cancer, prostate cancer, small cell lung cancer
Primary therapeutic area	Cancer

Development stage information

Phase lengths*

*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).

Most advanced stage of development (global)	Terminated at Phase 3
Status	Inactive
Start of clinical phase (IND filing or first Phase 1)	December 15, 2003
Start of Phase 2	January 19, 2006
Start of Phase 3	March 15, 2008
Date BLA/NDA submitted to FDA
Year of first approval (global)	None
Date of first US approval
INN, US product name	None
US or EU approved indications	None

Company information

Company	Pfizer
Licensee/Partner	Abgenix
Comments about company or candidate	Phase 3 study in NSCLS discontinued following an independent DSMC recommended the trial be stopped after concluding that the addition of figitumumab was unlikely to demonstrate a significant improvement on the primary endpoint. Phase 2 study in breast cancer was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns
Full address of company	66 Hudson Boulevard East, New York, NY 10001-2192 USA North America United States of America https://www.pfizer.com/contact

Description/comment

None

Additional information

Anticipated events	None
Factor(s) contributing to discontinuation	Business reasons